Science · Education
Evidence,
not advertising.
The Stria clinical team publishes long-form education on testosterone, peptides, recovery, and longevity — built for the patient who wants to understand what they’re putting in their body.
— Latest
Recently published.
01
Peptide Research Report · May 5, 2026 · 8 min read
The Great Compounding Reversal, CagriSema's Report Card, and the May 2026 Cardiometabolic Pipeline
The February 2026 HHS reversal restores Category 1 access for BPC-157, Thymosin Alpha-1, CJC-1295, and MOTS-c. Plus the latest data on CagriSema, Survodutide, MariTide, Mazdutide, and the emerging Picobody and Graspetide classes.
02
Peptide Research Report · April 29, 2026 · 7 min read
Retatrutide, Amylin Analogs, and the Rise of Muscle-Preserving Research
A research update covering Retatrutide Phase 3 data, emerging amylin analogs, and myostatin inhibitors for lean-mass preservation in the GLP-1 era.
— Up next
The clinical foundations.
Five long-form guides currently in the editorial queue. Subscribe in the assessment flow to be notified when each lands.
01
Coming soon · 12 min read
Understanding Testosterone Levels A complete guide.
What total, free, and bioavailable testosterone actually mean — and which ranges matter for symptom-driven men.
02
Coming soon · 9 min read
Total vs Free Testosterone What the numbers mean.
Why SHBG, albumin, and binding chemistry change the headline number — and how providers actually read your labs.
03
Coming soon · 8 min read
Symptoms of Low Testosterone In men under 40.
The presentation in 30s-and-40s men is different from older cohorts. Fatigue, recovery deficits, and cognitive fog.
04
Coming soon · 11 min read
TRT vs Natural Optimization When each makes sense.
Sleep, training, and nutrition fix more than people assume. When labs and symptoms say it's still time for TRT.
05
Coming soon · 14 min read
Peptides Explained BPC-157, Sermorelin, and more.
The mechanisms, evidence base, and indications for the peptides we actually prescribe — and the ones we don't.